|Toxiciy Grade:||4||City/State/Province:||Houston, Texas|
|Treatments:||Biologic therapy, Immunotherapy||Hospital:||The Methodist Hospital Research Institute|
Patients: The phase I/II study involved a total of 52 patients with metastatic renal cell carcinoma.
Treatment: The treatment consisted of a combination of biological therapy (thalidomide) and immunotherapy (interleukin-2).
Toxicity: For phase I, toxicities included: grade 3/4 fluid retention and grade 3 constipation. For phase II, toxicities included: grade 4 fatigue and skin toxicities.
Results: Overall median survival was not reported. Survival for individual patients ranged from a low of 1 month (1 patient) to a high of over 45 months (1 patient).
Support: One of the authors has received a grant from Celegene Corporation. Celgene manufactures and/or markets thalidomide.
Correspondence: Robert J. Amato, D.O.